I wrote briefly a few months ago about Altos Labs. It’s a new kind of biotech institute that is focused on cellular reprogramming. Now we know much more and it’s clear this is a huge deal. What’s in this article What is Altos Labs? | Cellular rejuvenation | Reprogramming oldness | Challenges | Altos Strategies | Analysis of […]
All about Altos Labs and $3B cellular rejuvenation push Read More »
Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end
Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »
When I read about Elizabeth Holmes and her blood testing startup Theranos I see parallels to hucksters in the arena of stem cells and cell therapy. I’m thinking especially of the unproven stem cell clinics out there. It goes farther than that though too, including people who aren’t hucksters at all but get caught up
Elizabeth Holmes, Theranos, & lessons for the stem cell field Read More »
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021
16 predictions for stem cells & regenerative medicine in 2022 Read More »
Happy New Year and get ready for another 364 more days of stem cell excitement and craziness in 2022. In the next day or two I’ll post my predictions for this new year. Recommended reads EO Wilson obit by Carl Zimmer in NYT. Who’s the next EO Wilson or someone like him with such big impact these
Weekly stem cell reads: COVID kidney, FDA letter, H3.3, EO Wilson Read More »
The past year was all over the place for the stem cell and regenerative medicine field. As you can see in my scoring of my 21 predictions for 2021, quite a few things were surprises in terms of what did and didn’t happen. Here’s an overview of the top stories of the year in our
Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court Read More »
We’ll begin this week’s recommended reads with some news on two wonderful stem cell scientists. While there are thousands of stem cell scientists, some stand out for their especially creative work. News on stem cell scientists Nobel laureate Yamanaka to retire as director of iPS cell center, Asahi Shimbun. Dr. Yamanaka will spend more time
Recommended reads: stem cell scientists, eggs from blood, Cryo-Cell Read More »
The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current
Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
A type of human cells used in research called HEK cells or 293s has been much in the news lately. This is mainly related to COVID-19 vaccine research. There seem to be many misunderstandings about 293 cells. For that reason, I thought I’d do this post to clear things up. I’ve been working with these
Explainer on 293 or HEK cells and their use in COVID vaccine research Read More »